ERRATUM

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

F Jakob, H Oertel¹, B Langdahl², O Ljunggren³, A Barrett⁴, D Karras⁵, J B Walsh⁶, A Fahrleitner-Pammer⁷, G Rajzbaum⁸, C Barker⁴, W F Lems⁹ and F Marin⁴

The authors and the journal apologise for errors that appeared in Figure 2 of this article published in the January issue, Vol **166**, pp 87–97. The errors relate to the number of asterisks given to represent the *P*-values for odd ratios (OR) of the comparisons with 0 to <6 months interval. In Figure 2a, the correct data should read as

6 to <12 months vs 0 to <6 months: OR 0.66 (95% CI: 0.45 to 0.98)*

12 to <18 months vs 0 to <6 months: OR 0.63 (95% CI: 0.41 to 0.96)*

and in Figure 2b, the correct data should read as:

12 to <18 months vs 0 to <6 months: OR 0.38 (95% CI: 0.18 to 0.82)*

and not as published. The correct figure and legend is given below.

European Journal of Endocrinology **166** 563

Figure 2 Risk of fracture (adjusted odds with 95% confidence intervals (CIs)) by fracture type: (a) all fractures pooled, (b) clinical vertebral, (c) non-vertebral, and (d) main non-vertebral, in each 6-month interval for the prior bisphosphonate user group. Note: Odds ratios (OR) and 95% confidence intervals (CI) for the comparison with the first 6 months of treatment are given where significant. **P*<0.05; ***P*<0.01; ****P*<0.001 vs. 0 to <6 months interval. Main non-vertebral fractures includes forearm/wrist, hip, humerus, leg and sternum/ribs.